[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Mori N, Sawada T, Satoh H, Kawaguchi M, Hara H, Matsushita K: A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung. JOP; 2008;9(6):698-703
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We report herein an unusual case of secondary tumor of the pancreas (primary tumor: adenocarcinoma of the lung) with hopefully curative resection.
  • The interval between the surgical treatment of lung cancer and the metachronous pancreatic metastasis was 22 months; there has been no recurrence of disease during the 24 months of follow-up after a pylorus-preserving pancreaticoduodenectomy.
  • CONCLUSION: Surgical treatment should be considered in patients with pancreatic metastasis from other organs if the disease is localized in the pancreas or if metastasis in other organs is controlled with chemotherapy and/or radiotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Back Pain / etiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Shoulder Pain / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Hashimoto M, Umekita N, Noda K: Non-Hodgkin lymphoma as a cause of obstructive jaundice with simultaneous extrahepatic portal vein obstruction: a case report. World J Gastroenterol; 2008 Jul 7;14(25):4093-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography (CT) revealed a 10 cm mass in the retroperitoneal space behind the head of the pancreas causing obstruction of the distal bile duct and the PV.
  • A pylorus-preserving pancreaticoduodenectomy combined with a PV resection was performed.
  • The pathologic diagnosis was diffuse large B-cell type non-Hodgkin lymphoma and the patient was transferred to the Department of Hematology and Oncology for chemotherapy.
  • He received four cycles of combined chemotherapy including cyclophosphamide, doxorubicin, vincristine and prednisone plus rituximab, and three cycles of intrathecal chemoprophylaxis including methotorexate, cytosine arbinoside and prednisone.
  • The patient is alive with no evidence of the disease for 7 mo after operation and will receive additional courses of chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Bile Ducts / pathology. Chemotherapy, Adjuvant. Humans. Jugular Veins / transplantation. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1188-94 [10811326.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):43-9 [11466812.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Surg Today. 2003;33(1):72-4 [12560914.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):845-9 [12854111.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2323-32 [17406815.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 May 1;71(9):2813-6 [7682150.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):485-8 [9764999.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):610-1 [15812422.001]
  • [Cites] J Gastrointest Surg. 2007 Jul;11(7):813-9 [17440790.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):503-7 [1323924.001]
  • (PMID = 18609698.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2725353
  •  go-up   go-down


3. Uesato M, Nabeya Y, Miyazaki S, Aoki T, Akai T, Shuto K, Tanizawa T, Miyazaki M, Matsubara H: Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach. World J Gastrointest Endosc; 2010 Oct 16;2(10):349-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach.
  • We report on a case of a 74 year old man who was diagnosed with a recurrence of non-invasive carcinoma of intraductal papillary mucinous neoplasm (non-invasive IPMN) by postoperative gastroscopy (GS).
  • A pylorus preserving pancreatico duodenectomy for IPMN in the pancreatic head was performed.
  • At first, the local recurrence of the tumor around the superior mesenteric artery circumference was diagnosed and disappeared with gemcitabine.
  • Later, the GS showed the elevated lesion with mucin hypersecretion in the remnant stomach.
  • We diagnosed a recurrence of IPMN and administered chemotherapy again.
  • It should be remembered that the elevated lesion of the remnant stomach is considered as one of the recurrent patterns of IPMN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160585.001).
  • [ISSN] 1948-5190
  • [Journal-full-title] World journal of gastrointestinal endoscopy
  • [ISO-abbreviation] World J Gastrointest Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999103
  • [Keywords] NOTNLM ; Endoscopy / Fistula / Intraductal papillary mucinous neoplasm / Recurrence / Stomach
  •  go-up   go-down


Advertisement
4. Kim SC: [Surgical management of pancreatic cancer]. Korean J Gastroenterol; 2008 Feb;51(2):89-100
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although significant progress has been made in the surgical treatment in terms of increased resection rate and decreased treatment-related morbidity and mortality, the true survival rate still remains below 5% today.
  • Surgical options for pancreatic cancer are based on the its unique anatomy and physiology, catastrophic tumor biology, experience of surgeon, and status of patients.
  • Four main options exist for the surgical treatment of pancreatic cancer.
  • These include standard "Whipple" pancreaticoduodenectomy (PD), pylorus preserving PD (PPPD), distal pancreatectomy (left-side pancreatectomy), and total pancreatectomy according to the location of tumor.
  • Portal vein involvement by tumor is regarded as an anatomical extension of disease, and en bloc resection of portal vein with tumor is recommended if technically feasible, which is stated in 2002 AJCC tumor staging for pancreatic cancer.
  • PPPD may be superior to standard PD in respect to nutrition and quality of life without any deleterious effect upon long term survival or tumor recurrence.
  • New surgical treatment modalities including modified extended pancreatectomy, neoadjuvant chemotherapy, and radical antegrade modular distal pancreatectomy have been tried to improve the patients' survival.
  • However, early diagnosis and treatment remain as key factors for the cure of pancreatic cancer irrespective of various surgical trials.
  • [MeSH-minor] Humans. Neoplasm Staging. Pancreaticoduodenectomy. Portal Vein / pathology. Portal Vein / surgery. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349571.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 57
  •  go-up   go-down


5. Matsumoto M, Udagawa I, Yasutomi J, Kusashio K, Kasagawa T, Tonooka T, Tashima Y, Irabu S, Nobumoto D, Suzuki M, Fukao K: [A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1407-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy].
  • A 65-year-old man with common bile duct cancer was treated by pylorus-preserving pancreaticoduodenectomy with D2 lymph node dissection.
  • Three months after surgery, tumor marker was increasing, and CT demonstrated multiple liver metastatic tumors.
  • Single drug chemotherapy with S-1(100 mg/body/day)was administered.
  • S-1 may be the chemotherapy of choice for recurrence of bile duct cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701860.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


6. Lee EY, Kim C, Kim MJ, Park JY, Park SW, Song SY, Chung JB, Kim H, Bang S: Signet ring cell carcinoma of the extrahepatic bile duct. Gut Liver; 2010 Sep;4(3):402-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most tumors affecting the extrahepatic bile duct are adenocarcinomas; the other histologic types occur only rarely.
  • Computed tomography and positron emission tomography suggested the presence of distal extrahepatic bile-duct cancer.
  • He underwent a pylorus preserving pancreaticoduodenectomy.
  • A histologic study confirmed a signet ring cell neoplasm of the distal common bile duct.
  • Because the upper resection margin was invaded by the tumor, he received postoperative concurrent chemoradiotherapy and four cycles of chemotherapy.
  • This is the second case of primary SRCC of the distal extrahepatic bile duct reported in the literature; further reports of cases are warranted to determine the nature of SRCC in the extrahepatic bile duct.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981222.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2956357
  • [Keywords] NOTNLM ; Extrahepatic bile duct / Signet ring cell carcinoma
  •  go-up   go-down


7. Chakravarty KD, Hsu JT, Liu KH, Yeh CN, Yeh TS, Hwang TL, Jan YY, Chen MF: Prognosis and feasibility of en-bloc vascular resection in stage II pancreatic adenocarcinoma. World J Gastroenterol; 2010 Feb 28;16(8):997-1002
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively analyzed 87 patients with stage II pancreatic adenocarcinoma, who were subjected to pancreaticoduodenectomy (PD) and pylorus-preserving PD (PPPD) between 1996 and 2006 in Chang Gung Memorial Hospital, Taiwan.
  • In multivariate analysis, serum bilirubin, histological differentiation and adjuvant chemotherapy were independent prognostic factors that influenced survival.
  • CONCLUSION: In stage II adenocarcinoma of the pancreatic head and uncinate process, serum bilirubin, histological differentiation and adjuvant chemotherapy were independent prognostic factors, and en-bloc vascular resection is a feasible option in carefully selected patients.
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreas / anatomy & histology. Pancreas / pathology. Pancreas / surgery. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Nov;2(4):605-8 [14627529.001]
  • [Cites] Am J Surg. 2003 Aug;186(2):149-53 [12885608.001]
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):122-6; discussion 126-7 [8383381.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):102-7 [7906180.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):352-4 [7943594.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Ann Surg. 1995 Mar;221(3):241-8 [7717777.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):154-62 [8597509.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Hepatol. 1998 Jun;28(6):1000-7 [9672176.001]
  • [Cites] World J Surg. 1999 Sep;23(9):926-9 [10449822.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):540-4; discussion 544-7 [16192814.001]
  • [Cites] Hepatogastroenterology. 2005 Sep-Oct;52(65):1596-600 [16201124.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1526-35 [16855797.001]
  • [Cites] J Gastrointest Surg. 2006 Sep-Oct;10(8):1106-15 [16966029.001]
  • [Cites] Pancreas. 2006 Oct;33(3):240-5 [17003644.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Arch Surg. 2007 Feb;142(2):172-9; discussion 180 [17309969.001]
  • [Cites] Surgery. 2007 Sep;142(3):313-8 [17723881.001]
  • [Cites] Oncology. 2007;72(5-6):314-21 [18187951.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3257-62 [10626197.001]
  • [Cites] Gut. 2000 May;46(5):725-31 [10764720.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):786-95 [11088073.001]
  • [Cites] Surgery. 2001 Feb;129(2):158-63 [11174708.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):726-34 [11400966.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):120-9 [11574081.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):263-6 [12630036.001]
  • [Cites] Ann Surg. 2003 Apr;237(4):509-14 [12677147.001]
  • [Cites] Acta Chir Scand. 1987 Nov-Dec;153(11-12):665-8 [3434110.001]
  • (PMID = 20180240.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2828606
  •  go-up   go-down


8. Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. Am Fam Physician; 2006 Feb 1;73(3):485-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: diagnosis and management.
  • More than one half of cases have distant metastasis at diagnosis.
  • Computed tomography is the most useful diagnostic and staging tool.
  • Resectable tumors are treated with the Whipple procedure or the pylorus-preserving Whipple procedure.
  • Adjuvant fluorouracil-based chemotherapy may prolong survival.
  • For nonresectable tumors, chemotherapy with gemcitabine prolongs survival.
  • Radiation combined with chemotherapy has slowed progression in locally advanced cancers.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Physical Examination. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477897.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


9. Hazama K, Suzuki Y, Takahashi M, Takahashi Y, Yoshioka T, Takano S, Kondoh S, Katoh H: Primary small cell carcinoma of the common bile duct, in which surgical treatment was performed after neoadjuvant chemotherapy: report of a case. Surg Today; 2003;33(11):870-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of the common bile duct, in which surgical treatment was performed after neoadjuvant chemotherapy: report of a case.
  • In this case, neoadjuvant chemotherapy followed by pylorus-preserving pancreaticoduodenectomy showed an excellent response.
  • To our knowledge, this is the first reported case of small cell carcinoma of the CBD in which a radical resection was performed after successful neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Biopsy, Needle. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14605962.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Tazawa K, Matsui K, Morita S, Yoshida T, Shinbo M, Yamagishi F, Yamada A, Tsukada K: [A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1869-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy].
  • We reported a case of unresectable gastric cancer presenting pylorus stenosis treated orally by S-1 therapy in a 72-year-old man who underwent gastrojejunostomy.
  • Detailed examination showed gastric cancer with pylorus stenosis.
  • After the operation, intake therapy of S-1 was started (80-100 mg/body/dayx28 days).
  • After 2 courses of the therapy, gastrointestinal fiber showed clinically a partial response of the main tumor.
  • After 3 courses of this treatment, the tumor presented multiple liver metastases as a clinically progressive disease state.
  • Paclitaxel therapy was conducted at a dose of 80 mg/body/weekx3 timesx2 courses.
  • The patient had no effective benefits from the treatment and died of the cancer.
  • He had survived 9 months, and the intervals of the intake and home stay were 7.5 months and five months, respectively, after the operation with no side effect of the chemotherapy.
  • Survival was no longer than for patients only operated without S-1 therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Gastric Bypass. Lymph Nodes / pathology. Oxonic Acid / administration & dosage. Pylorus / pathology. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Constriction, Pathologic. Drug Administration Routes. Drug Combinations. Humans. Lymphatic Metastasis. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


11. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, Saigusa N, Hayasaka A, Matsuzaki O, Miyazaki M: A case of small cell carcinoma of the common bile duct. Hepatogastroenterology; 2005 Mar-Apr;52(62):363-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and ultrasonography showed a mass near the pancreas head and dilatation of the intrahepatic bile ducts.
  • Upon laparotomy, a tumor was found to be located in the middle common bile duct.
  • Pylorus-preserving pancreaticoduodenectomy was performed.
  • The main trunk of the portal vein and the right hepatic artery were resected concomitantly because of tumor involvement.
  • The patient then underwent two postoperative courses of systemic chemotherapy.
  • Nevertheless, she died of cancer recurrence eight months after the operation, which showed that the tumor had a highly lethal nature, with rapid and widespread dissemination.
  • Further therapeutic trials are needed to improve survival in such cases.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Common Bile Duct
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholangiopancreatography, Magnetic Resonance. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816436.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Welsch T, Büchler MW, Schmidt J: [Surgery for pancreatic cancer]. Z Gastroenterol; 2008 Dec;46(12):1393-403
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chirurgie des Pankreaskarzinoms.
  • Even after complete resection and adjuvant chemotherapy, the 5-year survival rate amounts to merely 20 - 25%.
  • Besides a high resistance to chemotherapy and early lympho- and haematogenic metastases, the reason for this is often tumour extension beyond the medial and dorsal resection margins.
  • In standardised pathological examinations cancer cells can be detected in the resection margins in about 75 % of the cases, which reflect the aggressive and infiltrative tumour growth and probably explains the high rate of local recurrence.
  • Standard operations for curative tumour resection are the pylorus-preserving pancreatoduodenectomy (PPPD) and the left pancreatic resection with splenectomy in cases of pancreas tail tumours.
  • In selected, individual cases, patients may benefit from neoadjuvant radiochemotherapy to down-stage an unresectable tumour with subsequent tumour resection, a metastasis resection, or a resection of a local recurrence.
  • An R0 resection and tumour-free lymph nodes (N0 stage) are the two factors that can provide the best prognosis for the patient with a median survival of 2 years and a good quality of life.
  • In order to achieve a further and urgently needed improvement in treatment results, one should consider, if possible, all suitable patients for enrolment in current clinical studies on neoadjuvant, surgical, or adjuvant therapy.
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreaticoduodenectomy / methods. Prognosis. Splenectomy / methods. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19053009.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 101
  •  go-up   go-down


13. Wagner M, Kulli C, Friess H, Seiler CA, Büchler MW: [Surgery of pancreatic carcinoma]. Swiss Surg; 2000;6(5):264-70
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chirurgie des Pankreaskarzinoms.
  • Pancreatic cancer is the third leading neoplasm of the gastrointestinal system and has a dismal prognosis.
  • The majority of patients are no more suitable for resection at time of diagnosis due to early development of distant metastases or major infiltration of adjacent structures.
  • However, due to the resistance of pancreatic cancer against radiation and chemotherapy, radical resection represents the only therapy with a potential for cure.
  • For the surgical treatment of pancreatic head cancer, the classical Whipple operation is still the standard procedure but during the last two decades, pylorus-preserving pancreatoduodenectomy has been evolved as a more conservative procedure in order to omit the consequences of partial gastrectomy.
  • For cancer of the pancreatic body and tail, distal pancreatectomy or total pancreatectomy represent the current standard treatment.
  • More radical methods like regional pancreatectomy and resection with extended lymph node dissection have failed so far to demonstrate any improvements in long-term survival compared to the standard types of resection.
  • To further improve the treatment of pancreatic cancer, prospectively randomized trials are needed to compare extended surgical procedures with the standard types of resection and the efficiency of various adjuvant therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11077494.001).
  • [ISSN] 1023-9332
  • [Journal-full-title] Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera
  • [ISO-abbreviation] Swiss Surg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Number-of-references] 99
  •  go-up   go-down


14. Fischer L, Friess H, Z'graggen K, Uhl W, Büchler MW: [Operative management in the treatment of pancreatic cancer]. Zentralbl Chir; 2003 May;128(5):390-5
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative management in the treatment of pancreatic cancer].
  • [Transliterated title] Operatives Management bei der Therapie des Pankreaskarzinoms.
  • Because of the resistance of pancreatic cancer against radiation and/or chemotherapy surgery is still the only possibility for cure.
  • However, about 80 % of patients with the diagnosis of pancreatic cancer are no more suitable for curative resection at the time of diagnosis because of local tumor infiltration or the presence of distant metastases.
  • However, the pylorus preserving Whipple has been established as a surgical alternative to the classical Whipple.
  • But compared to the classical Whipple or the pylorus preserving Whipple resection there is still no clear advantage in terms of long term survival.
  • The prospective European multicenter study ESPAC-1 firstly demonstrated a survival advantage for adjuvant chemotherapy (5-FU and folic acid) but no gain for radiochemotherapy in the treatment of patients with R0 or R1 resected pancreatic cancer in terms of prolongation of mean survival (19.7 months vs. 14.0 months).
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Therapy, Combination. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Folic Acid / administration & dosage. Folic Acid / therapeutic use. Hematinics / administration & dosage. Hematinics / therapeutic use. Humans. Multicenter Studies as Topic. Neoplasm Metastasis. Pancreaticoduodenectomy. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12813637.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Hematinics; 935E97BOY8 / Folic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Uchida K, Joseph JM, Gapany C, Chardot C: Modified digestive reconstruction with midgut transposition after pylorus-preserving pancreaticoduodenectomy for pancreatic head tumor in childhood. J Pediatr Surg; 2008 Oct;43(10):1932-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified digestive reconstruction with midgut transposition after pylorus-preserving pancreaticoduodenectomy for pancreatic head tumor in childhood.
  • We describe a new procedure of digestive reconstruction after pylorus-preserving pancreaticoduodenectomy in a 13-year-old girl presenting with a large solid and papillary epithelial neoplasm of the pancreatic head.
  • A midgut transposition (like in a cure of midgut malrotation) was easily performed after tumor removal with minimal additional dissection.
  • [MeSH-minor] Adolescent. Anastomosis, Roux-en-Y. Enzymes / therapeutic use. Exocrine Pancreatic Insufficiency / drug therapy. Exocrine Pancreatic Insufficiency / etiology. Female. Humans. Jejunum / surgery. Pylorus. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926236.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzymes
  •  go-up   go-down


16. Sawaki A, Mizuno N, Hoki N, Ishikawa H, Takagi T, Yamao K: [Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2301-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 56-years-old woman underwent a pylorus-preserving pancreaticoduodenectomy for carcinoma of the ampulla of Vater in October 2003.
  • Computed tomography showed multiple abdominal lymph node metastases.
  • The patient was treated with S-1 (80 mg/day, day 1-28, followed by 2 weeks rest) from November 2003.
  • Anti-tumor efficacy was confirmed to be partial response by Response Evaluation Criteria in Solid Tumors (RECIST).
  • [MeSH-major] Ampulla of Vater. Antimetabolites, Antineoplastic / therapeutic use. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / surgery. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079635.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


17. Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, Shimizu A, Hyodo M, Yasuda Y: Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP; 2010;11(1):36-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Although surgical resection is the only curative therapeutic option for recurrent or metachronous pancreatic carcinomas, most such cancers are beyond surgical curability.
  • CASE REPORTS: CASE#1 A 65-year-old male developed weight loss and diabetes mellitus 83 months after a pylorus-preserving pancreaticoduodenectomy followed by two years of adjuvant chemotherapy (5-fluorouracil plus leucovorin plus mitomycin C) for a pancreatic carcinoma in the head of the pancreas (stage IA).
  • An abdominal CT scan revealed a 3 cm tumor in the remnant pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant distal pancreatectomy was performed and a pancreatic carcinoma similar in profile to the primary lesion (stage IIB) was confirmed pathologically.
  • CASE#2 A 67-year-old male showed increased CA 19-9 levels 25 months after a distal pancreatectomy for a pancreatic carcinoma in the body of the pancreas (stage IA).
  • CONCLUSION: Remnant pancreatectomy can be considered a treatment option for recurrent or metachronous pancreatic carcinomas.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Fluorodeoxyglucose F18. Humans. Male. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Carditello A, Scisca C, Stilo F, Parisi A, Basile M: The possible role of radiofrequency as complementary treatment of locally advanced gastric cancer. Ann Ital Chir; 2005 Jan-Feb;76(1):39-41
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The possible role of radiofrequency as complementary treatment of locally advanced gastric cancer.
  • The possible use of a palliative treatment as radiofrequency ablation (the good results are note about the treatment of hepatic malignancies by colo-rectal cancer) is reported in recent series.
  • Therefore we decide to use radiofrequency ablation for the treatment of hepatic metastases by gastric cancer, difficulty treated surgically.
  • After repeated postoperative chemotherapy cycles, he presented metastases at IV hepatic segment.
  • Case 2: B.G., 63 year-old man, with advanced gastric adenocarcinoma (T4) at the pylorus and hepatic metastasis at IV segment.
  • After 7 months, the patient returned with marked jaundice for diffused hepatic metastases; he refused any treatment, and then he died one month after.
  • The results, limited by poor experience, may indicate the complementary role of the radiofrequency in the palliative treatment of the hepatic metastases by advanced gastric cancer, difficulty treated surgically.
  • [MeSH-major] Adenocarcinoma / surgery. Catheter Ablation. Liver Neoplasms / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035670.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Kim K, Kim S, Chie EK, Kim SW, Bang YJ, Ha SW: Postoperative chemoradiotherapy of pancreatic cancer: what is the appropriate target volume of radiation therapy? Tumori; 2005 Nov-Dec;91(6):493-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative chemoradiotherapy of pancreatic cancer: what is the appropriate target volume of radiation therapy?
  • AIMS AND BACKGROUND: To evaluate the influence of radiation therapy target volume on the treatment outcome of adjuvant chemoradiotherapy for pancreatic cancer after curative resection.
  • Whipple's operation was performed in 44 patients, pylorus-preserving pancreaticoduodenectomy in 14, distal pancreatectomy in 9, and subtotal pancreatectomy in 3.
  • Postoperative adjuvant radiotherapy was given up to 40 Gy at 2 Gy per fraction with a two-week planned rest.
  • Until 1991, whole pancreas or preoperative tumor volume and retroperitoneal lymph nodes were irradiated (extended field, n=14).
  • According to the radiotherapy target volume, the median survival time was 14 months in the extended field group and 16 months in the limited field group (P = 0.65).
  • CONCLUSIONS: From the viewpoint of the target volume of radiotherapy, a limited field did not worsen the treatment outcome, although the survival rate was poor in both groups.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatectomy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tumori. 2006 May-Jun;92(3):269; author reply 269 [16869252.001]
  • (PMID = 16457148.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, Fujita Y, Uchiyama K, Yamaue H: Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg; 2009 Mar;394(2):249-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 1999 and 2005, 68 patients for pancreatic adenocarcinoma underwent a pancreaticoduodenectomy (n = 17), a pylorus-preserving pancreaticoduodenectomy (n = 27), distal pancreatectomy (n = 22), or total pancreatectomy (n = 2) with an extensive lymph node dissection.
  • RESULTS: A tumor recurrence occurred to 55 patients (13 of the liver, 21 of the local recurrence, 16 of peritoneal dissemination, three of the lymph node, and two of lung).
  • The low tumor grade and female demonstrated a risk factor for a liver metastasis (P = 0.043, P = 0.031).
  • A logistic regression analysis demonstrated female (P = 0.02) and low tumor grade (P = 0.04) as independent risk factors for recurrence with liver metastasis.
  • The median survival time (MST) was 13.6 months, and MST of patients with a liver metastasis as an initial recurrent site was 13.7 months; the liver metastasis as an initial recurrent site has no impact on the MST after pancreatic resection.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Pilot Projects. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Pancreatology. 2002;2(2):79-88 [12123098.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Pancreas. 2002 Nov;25(4):366-72 [12409831.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):511-8 [16627216.001]
  • [Cites] Surgery. 2004 Nov;136(5):1003-11 [15523393.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Br J Surg. 1997 Oct;84(10 ):1370-6 [9361591.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Ann Surg. 1999 May;229(5):613-22; discussion 622-4 [10235519.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):361-4 [7943597.001]
  • [Cites] World J Surg. 1999 Sep;23(9):888-91 [10449815.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):304-9 [14993026.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Eur J Cancer. 1991;27(10 ):1258-63 [1835595.001]
  • [Cites] Cancer. 1993 Oct 1;72 (7):2118-23 [8104092.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):722-31 [15110805.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] J Am Coll Surg. 2006 Sep;203(3):345-52 [16931307.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):1-7 [16794381.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • (PMID = 18343944.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Hara A, Tsunemi S, Yamamoto M, Izumi N, Iwamoto S: [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2065-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
  • Paclitaxel was used as the first-line drug for treatment of a case with peritoneal recurrence of gastric cancer, accompanied by cancerous ascites.
  • Because paclitaxel was ineffective, TS-1 was used as the second-line drug, resulting in disappearance of cancerous ascites on diagnostic imaging.
  • In February 2004, he underwent resection of the pyloric side of the stomach (D 2) based on a diagnosis of advanced gastric cancer.
  • CT scans, conducted in February 2005, revealed ascites, and a diagnosis of cancerous peritonitis was made on the basis of subsequent cyto-diagnostic findings.
  • He was later hospitalized because of anorexia and difficulty with oral ingestion, and received paclitaxel therapy (60 mg/m(2)).
  • CT scans, obtained at the end of two cycles of TS-1 therapy, revealed complete disappearance of ascites.
  • This therapy was administered for 4 cycles in total.
  • CT scans, performed at the end of each cycle of TS-1 therapy, confirmed the absence of ascites.
  • Our experience with this case suggests that if paclitaxel therapy fails to exert satisfactory efficacy, switching to second-line TS-1 therapy is a promising means of treating gastric cancer complicated by cancerous peritonitis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Ascites / drug therapy. Drug Resistance, Neoplasm. Oxonic Acid / therapeutic use. Paclitaxel. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Male. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Pylorus / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197755.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement